Daniel Petrylak is an Oncology physician affiliated with Yale Cancer Center. OpenAlex indexes 13 publications with 3,609 citations (h-index 8); ClinicalTrials.gov lists 8 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
35 Park Street, Np-4
New Haven, CT 065101110
Telephone
203-200-4822Registry record last updated 12 Feb 2014.
Clinical trials
- A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer
Sponsor: Achieve Life Sciences
- Study of Bevacizumab and Erlotinib for Patients With Hormone Refractory Prostate Cancer
Sponsor: Columbia University
- S0400, FR901228 in Treating Patients With Advanced Cancer of the Urothelium
Sponsor: SWOG Cancer Research Network
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
41 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Astellas Pharma Europe LtdProgram year202523 payments$18,441openpaymentsdata.cms.gov ↗
- Merck Sharp & Dohme LLCProgram year20255 payments
- Janssen Biotech, Inc.Program year20254 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
1 NIH research award on record, funded 2018–2022 per NIH RePORTER. The latest:
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Avelumab First-Line Maintenance (1LM) for Advanced Urothelial Carcinoma (aUC): Long-Term Outcomes from JAVELIN Bladder 100 in Patients with Low Tumor Burden
Indian Journal of Medical and Paediatric Oncology
2026 - Avelumab First-Line (1L) Maintenance for Advanced Urothelial Carcinoma (aUC): Long-Term Outcomes from the JAVELIN Bladder 100 Phase 3 Trial in Patients (pts) with Histological Subtypes
Indian Journal of Medical and Paediatric Oncology
2026 - Final results of a phase I study of oral belinostat (PXD101) in patients with solid tumors
Journal of Clinical Oncology
2009
Similar KOLs
Other experts from the same institution or the same specialty.
Ian Krop, MD
Yale Cancer Center
Maryam Lustberg, MD
Yale Cancer Center
Pamela Kunz, MD
Yale Cancer Center
Anne Chiang, MD
Yale Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”